Announcement on Subsidiary Obtaining Implied Approval for Drug Clinical Trial

Guanhao Biotech Co., Ltd.·July 10, 2026·2 pages

✨ AI Summary

Guohao Biology's subsidiary, Beijing Tianyou Qiyuan, has received implied approval from the NMPA for its QY-iHEP02 injection. This drug is intended for treating decompensated cirrhosis. The company expects no significant short-term impact on its financial performance due to the long development cycle and uncertainties.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300238

Securities Abbreviation: Guohao Biology

Announcement Number: 2026-030

Guohao Biology Co., Ltd.

Announcement on Subsidiary Obtaining Implied Approval for Drug Clinical Trial

The Company and the entire Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Recently, Guohao Biology Co., Ltd. (hereinafter referred to as the "Company") learned through public channels that its holding subsidiary, Beijing Tianyou Qiyuan Biotechnology Co., Ltd. (hereinafter referred to as "Tianyou Qiyuan"), has obtained implied approval for clinical trials from the National Medical Products Administration for its "QY-iHEP02 Injection." The relevant situation is hereby announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.